In a wide range of tumors and cancer cell lines, including small-cell lung carcinoma, NSCLC, ovarian, prostate, bladder, uterine, upper gastrointestinal, colon, pancreatic, LASCCHN, and gastric cancer, βIII upregulation is associated with the development of resistance to taxane-based chemotherapy and poor clinical outcome [121,200,202,203,204,205,206,207,208,210,211,212,213,215,223,224,225,226,227,228,229,230,231,232,233]. Here, CACNA1B is linked to non-small cell lung carcinoma.